Introduction
Neuroinflammation plays a vital role in neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, HIV-associated dementia, multiple sclerosis, and stroke [1] . Chemokines, cytokines, nitric oxide (NO), reactive oxygen species, and prostaglandin E2 (PGE 2 ) play a pivotal role in modulating immune responses [2] . Microglia, the resident of macrophages within the central nervous system, are the primary effectors of neuroinflammation [3] . Microglial cells are activated by lipopolysaccharide (LPS), a component of the outer membrane of gram-negative bacteria, and generate neuroinflammation by releasing inflammatory mediators and cytokines such as NO, PGE 2 , tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-12 (IL-12), and interleukin-6 (IL-6) [4, 5] . Accordingly, regulation of microglial cell activation and production of these proinflammatory cytokines and mediators could provide a useful therapeutic approach to neurodegenerative diseases.
Nuclear factor-kappa B (NF-κB) is a crucial transcription factor that mediates inflammatory responses through regulation of the proinflammatory cytokines and chemokines in microglial cells [6, 7] . NF-κB is normally located in the cytoplasm as an inactive form, which is inhibited by inhibitor of kappa B-α (IκB-α). Following LPS stimulation, IκB-α is phosphorylated and ubiquitinated; the unbound NF-κB then translocates to the nucleus, where it binds to kappaB (κB) sites. NF-κB thus induces the transcription of target genes [8, 9] . In addition, NF-κB activity is modulated by mitogen-activated protein kinases (MAPKs) [10, 11] . MAPKs are one of the major kinase families involved in inflammatory processes. MAPKs such as extracellular signal regulated kinase (ERK), c-Jun NH 2 -terminal kinase (JNK), and p38 MAPK have all been shown to regulate NF-κB activation [12] . Previous research showed that JNK and p38 MAPK were associated with inflammation in the immune system [13] .
Results

Chemical structure of cudratricusxanthone L (1) and its effect on BV2 microglial cell viability
The chemical structure of cudratricusxanthone L (1), isolated from C. tricuspidata (Figure 1) , was determined in a previous study [17] . To identify the cytotoxic effects of cudratricusxanthone L (1), we conducted an MTT assay to investigate the viability of BV2 
Effects of cudratricusxanthone L (1) on the production of TNF-α, IL-1β, IL-12, and IL-6 by LPS-stimulated BV2 microglial cells
We evaluated the effects of cudratricusxanthone L (1), obtained from a methanol extract of C. tricuspidata, on the levels of TNF-α, IL-1β, IL-12, and IL-6 in the media of LPS-treated BV2 microglial cells ( Figure 3 ). The levels of these pro-inflammatory cytokines in media conditioned by LPS-treated BV2 microglial cells were reduced in cells exposed to cudratricusxanthone L (1) at a concentration range of 1.3-10.0 μM for 12 h. As shown in Figure 3A -3D, cudratricusxanthone L (1) reduced the levels of TNF-α, IL-1β, IL-12, and IL-6 in a concentration-dependent manner. 
Effects of cudratricusxanthone L (1) on IκB-α levels, NF-κB nuclear translocation, and NF-κB DNA binding activity in LPS-stimulated BV2 microglial cells
Firstly, we investigated the effects of cudratricusxanthone L on IκB-α degradation and phosphorylation. Moreover, we checked how this influenced NF-κB (p50 and p65) nuclear translocation. As shown in Figure 5A , IκB-α was degraded in BV2 microglia exposed to LPS for 1 h. However, cudratricusxanthone L (1) 
Effects of cudratricusxanthone L (1) on MAPK phosphorylation in BV2 microglial cells stimulated with LPS
As shown in Figure 6 , phosphorylation of ERK, JNK, and p38 were increased in BV2 
Effects of cudratricusxanthone L (1) on nitrite production, and iNOS and COX-2 protein expression, in LPS-stimulated rat primary microglial cells
Effects of cudratricusxanthone L (1) on the production of TNF-α, IL-1β, IL-12, and IL-6 by LPS-stimulated rat primary microglial cells
We checked the the levels of TNF-α, IL-1β, IL-12, and IL-6 mRNA expressions in LPStreated rat primary microglial cells ( Figure 8 ). The levels of these pro-inflammatory cytokines in media conditioned by LPS-treated rat primary microglial cells were reduced in cells exposed to cudratricusxanthone L (1) at a concentration range of 1.3-10.0 μM for 6 h.
As shown in Figure 8A -8D, cudratricusxanthone L (1) decreased the expressions of TNF-α, IL-1β, IL-12, and IL-6 in a dose-dependent manner. 
Effects of cudratricusxanthone L (1) on IκB-α levels, NF-κB nuclear translocation, and NF-κB DNA binding activity in LPS-stimulated rat primary microglial cells
As shown in Figure 8A , IκB-α was degraded after exposure of rat primary microglial 
Discussion
The present investigation demonstrated that cudratricusxanthone L, isolated from C.
tricuspidata, appeared to exert anti-neuroinflammatory effects in both BV2 and primary microglial cells, by inactivating NF-κB and MAPKs pathways. Plant-derived natural products and their bioactive constituents have been shown to have anti-inflammatory and antioxidant activities, and they could protect the brain against inflammatory damage [24, 25] . C.
tricuspidata is used as one of the traditional medical herbs for the treatment of inflammation, oxidative stress, and hepatosis [17, 27, 28] . Therefore, the present study investigated the antineuroinflammatory effects of a small-molecule constituent of C. tricuspidata
Microglial cells act as the macrophages of the central nervous system [29] . BV2 and primary microglial cells are used as in vitro models, in order to elucidate inflammatory reactions [30, 31] . The BV2 cell line is an immortalized murine microglial cell line, and primary microglial cells were isolated from rat cerebral cortices. Although these cells have some similar properties, the BV2 cell line does not have all the characteristics of microglial cells [32] . Thus, we tested the anti-inflammatory effects of cudratricusxanthone L in both BV2 and primary microglial cells, in order to determine the suitability of cudratricusxanthone L as an anti-neuroinflammatory agent for the treatment of various neurodegenerative diseases.
The expression of iNOS and COX-2 proteins is essential for immune-activated inflammatory cells, including microglial cells, because iNOS generates NO and COX-2 produces PGE 2 [33] . Thus, inhibition of iNOS and COX-2 can produce significant antineuroinflammatory effects. Pre-treatment with cudratricusxanthone L attenuated LPSmediated stimulation of iNOS and COX-2 protein expression, as well as reducing the production of NO and PGE 2 , in BV2 cells (Figure 4 ). Cudratricusxanthone L also appeared to inhibit the production of NO and iNOS/COX-2 expression in primary microglial cells ( Figure   7 ).
LPS-activated microglial cells show increased production of pro-inflammatory cytokines such as IL-1β, IL-6, TNF-α, and IL-12; these cytokines are associated with inflammatory responses [34] . Therefore, we investigated whether cudratricusxanthone L altered the production of pro-inflammatory cytokines in BV2 and primary microglial cells. This analysis found that cudratricusxanthone L attenuated the LPS-induced production of these proinflammatory cytokines in both BV2 ( Figure 3 ) and primary microglial cells (Figure 8 ).
Activated NF-κB promotes cellular signal transduction pathways that are related to the regulation of iNOS, COX-2, and various cytokines [35] [36] [37] . Therefore, blocking NF-κB transcriptional activity could provide an important tool for the treatment of neuroinflammatory diseases [38] . Pre-treatment with cudratricusxanthone L inactivated NF-κB pathways by inhibiting the phosphorylation and degradation of IκB-α, reducing nuclear translocation of p65 and p50 dimers, and suppressing the DNA binding activity of p65 in both BV2 ( Figure 5 ) and primary microglial cells ( Figure 9 ).
Furthermore, MAPK pathways are also involved in LPS-induced iNOS and COX-2 expression through regulation of NF-κB activation in microglial cells [39] . Thus, the effect of cudratricusxanthone L on LPS-induced MAPK activation was examined. This analysis indicated that cudratricusxanthone L inhibited JNK and p38 MAPK, leading to a reduction in LPS-induced iNOS and COX-2 expression (Figure 6 ).
Materials and Methods
Chemicals and reagents
Cudratricusxanthone L was obtained as described in our previous study [17, 21] . 
Cell culture and viability assay
BV2 microglial cells were obtained from Prof. Hyun Park at Wonkwang University (Iksan, Korea). These cells were maintained at 5 × 10 6 cells/100-mm diameter dish (5 × 10 5 cells/mL) in DMEM supplemented with 10% (v/v) heat-inactivated FBS, penicillin G (100 units/mL), streptomycin (100 μg/mL), and ʟ-glutamine (2 mM), and incubated at 37 °C in a humidified atmosphere containing 5% CO 2 . To determine cell viability, cells were plated in 96-well plates (2 × 10 4 cells/well) prior to incubation with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) at a final concentration of 0.5 mg/mL for 4 h; the formazan produced was then dissolved in acidic 2-propanol. Optical density was measured at 590 nm using a microplate reader (Bio-Rad, Hercules, CA, USA). The optical density of the formazan formed in control (untreated) cells was considered to represent 100% viability. The assay was conducted three times independently.
Primary microglial culture
Cells dissociated from the cerebral hemispheres of 1 day-old postnatal rat brains (Sprague-Dawley strain) were seeded at a density of 1.2 × 10 6 cells/mL in DMEM (Gibco)
containing 10% FBS and 1% penicillin-streptomycin in a T-75 flask (SPL Life Sciences, Pocheon, Korea). Two weeks later, microglia were detached by mild shaking and filtered through a cell strainer (BD Falcon, Bedford, MA) to remove astrocytes. After centrifugation (1000 × g) for 5 min, cells were resuspended in fresh DMEM containing 10% FBS and 1%
penicillin-streptomycin before plating at a final density of 1.5 × 10 5 cells/well on a 24-well culture plate. After 2 h, the medium was changed for DMEM containing 5% FBS and 500 μM B27 supplement (Gibco).
Nitrite determination
As an indicator of NO production, the nitrite concentration in the medium was measured using the Griess reaction. Three independent assays were performed. Each aliquot of conditioned medium (100 µL) was mixed with an equal volume of Griess reagent (Solution A:
222488, Solution B: S438081; Sigma-Aldrich), and the absorbance of the mixture at 525 nm was determined using a microplate reader.
PGE 2 assay
The level of PGE 2 present in cell culture medium was determined using a commercially available kit from R&D Systems (Minneapolis, MN). Three independent assays were performed according to the manufacturer's instructions. Briefly, BV2 microglial cells were cultured in 24-well plates, pre-incubated for 3 h with different concentrations of cudratricusxanthone L, and then stimulated for 24 h with LPS. Cell culture media were collected immediately after treatment and spun at 13,000 × g for 2 min to remove particulate matter. The medium was added to a 96-well plate pre-coated with affinity-purified polyclonal antibodies specific for PGE 2 . An enzyme-linked polyclonal antibody specific for PGE 2 was added to the wells and incubated for 24 h, followed by a final wash to remove any unbound antibody. A substrate solution was then added and the intensity of color produced, measured at 450 nm, was proportional to the amount of PGE 2 present. 
Preparation of cytosolic and nuclear fractions
DNA binding activity of NF-κB
BV2 microglial cells were pre-treated for 3 h with the indicated concentrations of cudratricusxanthone L prior to stimulating for 1 h with LPS (1 μg/mL). The DNA-binding activity of NF-κB in nuclear extracts was measured using the TransAM ® kit (Active Motif, Carlsbad, CA, USA) according to the manufacturer's instructions. The assay was conducted three times independently.
Western blot analysis
BV2 and primary rat microglial cells were harvested and pelleted by centrifugation at 16,000 rpm for 15 min. The cells were then washed with phosphate-buffered saline and lysed in 20 mM Tris-HCl buffer (pH 7.4) containing a protease inhibitor mixture (0.1 mM phenylmethylsulfonylfluoride, 5 mg/mL aprotinin, 5 mg/mL pepstatin A, and 1 mg/mL chymostatin). The protein concentration was determined using a Lowry protein assay kit (P5626; Sigma-Aldrich). An equal amount of protein from each sample was resolved using 7.5% or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then electrophoretically transferred onto a Hybond™ enhanced chemiluminescence nitrocellulose membrane (Bio-Rad). The membrane was blocked with 5% (w/v) skim milk before sequential incubation with the primary antibody (Santa Cruz Biotechnology, CA, USA) and the horseradish peroxidase-conjugated secondary antibody, followed by detection using enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The signal intensities were quantified using densitometric ImageJ software (National Institutes of Health, Bethesda, MD, USA). Molecular weight markers were used, as were the internal standards, β-actin and PCNA. The analysis was conducted three times independently. 
NF-κB localization and immunofluorescence
Statistical analysis
The data were expressed as the mean ± standard deviation (SD) of at least three independent experiments. To compare three or more groups, one-way analysis of variance followed by Tukey's multiple comparison tests was performed. Statistical analysis was conducted using GraphPad Prism software, version 3.03 (GraphPad Software Inc., San Diego, CA, USA).
Conclusions
The present study showed that cudratricusxanthone L had anti-neuroinflammatory effects in BV2 and primary microglial cells. This compound inhibited the overexpression of proinflammatory mediators such as iNOS, COX-2, NO, PGE 2 , and pro-inflammatory cytokines; these effects were clearly related to an inactivation of the NF-κB pathway. In addition, cudratricusxanthone L repressed the phosphorylation of JNK and p38 MAPK in BV2 cells.
Therefore, cudratricusxanthone L isolated from C. tricuspidata has the potential to be used as a therapeutic agent for the treatment of neuroinflammation and related neurodegenerative diseases. this study, contributed to the isolation and structure determination of the compound, and assisted in writing the manuscript.
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